Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
[ad_1] Michael Siluk | UCG | Universal Images Group | Getty Images Novo Nordisk rose as much as 4% after England’s drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of […]
Trump says he thinks he will have the ‘honor’ of ‘taking Cuba’
[ad_1] A tricycle is decorated with U.S. and Cuban flags in Havana on Feb. 26, 2026. Yamil Lage | AFP | Getty Images President Donald Trump on Monday said he thinks he will have the “honor” of “taking Cuba,” speaking during an executive order signing at the White House. “Whether I free it, take it, […]
‘Please, please, please’: Denmark urges citizens to avoid driving as oil prices spike
[ad_1] Gasoline prices at a Uno-X gas station in Copenhagen, Denmark, on March 9, 2026. Nurphoto | Nurphoto | Getty Images Denmark’s energy minister urged citizens of the Scandinavian country to cut back on energy use and ditch cars as the price of oil continues to skyrocket amid the Middle East conflict. Lars Aagaard, Denmark’s […]
These 4 charts show the scale of Novo Nordisk’s woes
[ad_1] Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks […]
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
[ad_1] Analysts added to the sour mood around Novo Nordisk , racing to cut price targets on the stock, after the Danish drugmaker published disappointing trial results on what it hoped to be its next big weight loss drug. The drug, CagriSema didn’t meet the key goal of matching rival medicine Zepbound, developed by Eli […]
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
[ad_1] Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s […]